INDUSTRIAL HEMP VS MEDICAL CANNABIS
All premium Prana Principle cannabinoid-rich items that we market are derived from organically cultivated industrial hemp. Both medical cannabis and industrial hemp are of the same plant: Cannabis sativa L. The key distinction—and what makes industrial hemp-derived products widely available—is the legal limit of the psychoactive Delta 9 Tetrahydrocannabinol (THC) molecule.
“Industrial Hemp” is defined by new federal legislation as a product or products derived from Cannabis Sativa L that contain less than 0.3% delta-9 tetrahydrocannabinol (THC) on a dry weight basis. The 2018 Farm Bill (signed into law on December 20th, 2018) re-schedules industrial hemp and various derivatives thereof, including CBD, from the Controlled Substances Act when produced in compliance with a state hemp program. This change presents new opportunities for compliant companies to offer qualified CBD products in new markets. We take this a step further using a proprietary isolation chromatography extraction process that eliminates 100% of active THC. We then verify product quality, consistency, and compliance by third-party lab testing each batch of product we produce.
PRANA PRINCIPLE™ PRODUCTS CONTAIN 0.0% THC
THE HUMAN ENDOCANNABINOID SYSTEM (HECS) CB₁&CB₂ RECEPTORS
Scientists have begun to understand the Human Endocannabinoid System (HEcS) after a few decades of research. The HEcS has been known to be one of the most important discoveries in human physiology. Research has uncovered the responsibility of the HEcS in maintaining and controlling homeostasis in the body through two known receptors called CB1 and CB2.
This process is known as “The Entourage Effect.” Scientists suggest that most people suffer from “Cannabinoid Deficiency” as the body produces its own endogenous cannabinoids. “Cannabinoid Deficiency” causes the HEcS to operate less efficiently. Adding broad spectrum phytocannabinoids to our diets may assist in achieving optimal health. *
The primary cannabinoid receptors are identified as Cannabinoid type 1 receptors (CB1) and Cannabinoid type 2 receptors (CB2).
These receptors can accept the following types of cannabinoids:
- Endocannabinoids: Endogenous-fatty-acid cannabinoids naturally produced in the body (e.g., anandamide and 2-AG)
- Phytocannabinoids: Concentrated in the resin of flowers and leaves in plants such as Cannabis Sativa L (e.g., THC and CBD)
- Synthetic Cannabinoids: Manufactured by artificial means in a laboratory.
Science has shown that CB1 is not only detected in the brain, but also in many other organs, connective tissues, gonads, and glands; however, CB1 receptors are not found in the medulla oblongata, the part of the brain stem responsible for cardiovascular and respiratory functions. CB1 receptors are known to play a role in coordination, spatial orientation, sensory perceptions, cognitive function, and motivation. Another important function of CB1 receptors is the reduction of excessive or inadequate signaling of neurotransmitters in the brain. The activation of CB1 via cannabinoid therapy can help to regulate the hyperactivity and hypoactivity of the neurotransmitters (e.g., serotonin and dopamine) *.
CB2 receptors are associated with the immune system and are found outside the brain including the gut, spleen, liver, heart, kidneys, and bones. Evidence has shown the beneficial therapeutic strategy of using CBD to reduce the impact of inflammatory and neuro-inflammatory diseases. Studies now show that CB2 also plays a role in the signal processing in the brain, whereas until recently, it was unknown that CB2 had any role relating to nerve cells or bundles. *
There is a third receptor called the transient receptor potential vanilloid-type one (TRPV1). Unlike the primary receptors CB1 CB2, TRPV1 detects and regulates body temperature. It is responsible for the sensations of external heat and pain and is subject to desensitization. If the pathway is continuously stimulated, it will eventually slow down or even stop. This raises the therapeutic possibilities for agents to effectively treat certain neuropathic pain with Cannabinoid therapy. *
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.